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1. Introduction  
The goal of treatment of osteoporosis is to decrease the risk of fractures in patients with high 
risk for a first or subsequent fracture. The efficacy of treatment will depend on the efficacy 
and level of accomplishment of case finding to select patients at risk, the results of 
additional investigations, the efficacy, tolerance, and safety of medical intervention, and the 
adherence to treatment during follow-up. Each of these steps is critical in treatment in daily 
clinical practice. Failure to consider one or other step can result in suboptimal fracture 
prevention or overtreatment (Geusens, 2009). 
On the other hand, measurement of bone mineral density (BMD), assessment of the fracture 
risk, and making decisions regarding to appropriate therapeutic intervention are the 
ultimate goal when evaluating patients for osteoporosis (NIH Consensus Development 
Panel on Osteoporosis Prevention, Diagnosis, and Therapy, 2001). Since many fractures 
among postmenopausal women occur in those with T-scores better than in the osteoporotic 
range (Siris et al, 2004; Schuit et al, 2004; Cranney et al, 2007), screening of the patients at 
high risk of fracture and early diagnosis are important.  
2. Screening of osteoporosis 
The aim of screening is obviously to direct interventions to those most in need, and to avoid 
treatment of healthy individuals who will never fracture. Bone mass is used conventionally 
as a proxy of overall bone strength and low bone mass is a major risk factor for osteoporotic 
fractures. Although BMD measurement is the standard test for the diagnosis of osteoporosis 
before fracture, ongoing research indicates that BMD measurement alone may not be 
adequate for detection of individuals at high risk of fracture (Kanis, 1994). Epidemiological 
studies have shown that a substantial proportion of osteoporotic fractures occur in 
postmenopausal women who do not meet BMD criteria for osteoporosis defined according 
to the WHO definition as a T-score of -2.5 or below (Siris et al, 2004; Schuit et al, 2004; 
Cranney et al, 2007). This suggests that factors other than BMD contribute to a patient’s risk 
of fracture. Central dual-energy x-ray absorptiometry (DXA) is not available everywhere. 
Furthermore, although BMD measurement is specific, it lacks sensitivity when used alone, 
so that a number of high-risk patients escape identification (Kanis, 1994). Thus, the potential 
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impact of extensive population-based screening with BMD in women at the time of 
menopause on the burden of fractures is less than optimal; screening the general population 
with BMD would not be cost-effective and is considered inadvisable in many countries 
(World Health Organization [WHO], 2004). In practice, most guidelines recommend using 
risk factor assessment tools such as Fracture Risk Assessment Tool FRAX® to help select 
patients for BMD measurement and/or treatment. 
The National Osteoporosis Foundation (NOF), US Preventive Services Task Force (USPSTF), 
and the American Association of Clinical Endocrinologists (AACE) recommend that BMD 
testing should be performed to guide treatment decisions, based on the patient’s risk profile 
(National Osteoporosis Foundation [NOF], 2003; US Preventive Services Task Force 
[USPSTF], 2002; Hodgson et al, 2001). Also, the NOF recommends that all postmenopausal 
women and men age 50 and older should be evaluated clinically for osteoporosis risk in 
order to determine the need for BMD measurement and considered the possibility of 
osteoporosis and fracture risk in men and women, based on the presence of the risk factors 
and conditions (NOF, 2010). 
The National Osteoporosis Guideline Group (NOGG) recommends that patients are 
identified opportunistically using a case-finding strategy on the finding of a previous 
fragility fracture or the presence of significant clinical risk factors because, at present, there 
is no universally accepted policy for population screening in the UK to identify individuals 
with osteoporosis or those at high risk of fracture (Compston et al, 2009). 
3. Diagnosis of osteoporosis 
Osteoporosis is diagnosed on the basis of either a low-impact or fragility fracture or a low 
BMD. A low-impact fracture is one that occurs after a fall from standing height or less; a 
fragility fracture occurs spontaneously or with no trauma (cough, sneezing, sudden 
movement) (Mauck & Clarke, 2006).  
Until recent years, diagnosis of non-fractured patients was based on the quantitative 
assessment of BMD, usually by central DXA. In 1994, the World Health Organization 
(WHO) developed a definition of osteoporosis on the basis of studies of women of various 
ages (Table 1) (Kanis et al, 1994). The BMD, measured with DXA, results are reported as a 
density measurement in gm/cm2, in addition to T- and Z-scores. 
 
Category Fracture Risk Action 
Normal 
T-score at -1.0 or above 
Below average Be watchful for clinical triggers 
Osteopenia 
T-score between 
 -1.0 and -2.5 
Above average Consider prevention in peri- or post-MPW 
Be watchful for clinical triggers 
Possibly repeat investigations in 2-3 years 
Osteoporosis 
T-score at -2.5 or below 
High Exclude secondary causes
Therapeutic intervention indicated in most 
patients 
Severe Osteoporosis
T-score at -2.5 or below and 
already experienced one or 
more fractures 
Established
osteoporosis 
Exclude secondary causes
Therapeutic intervention indicated in most 
patients 
Table 1. Definition of osteoporosis by the WHO 
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The T-score represent the number of SDs from the mean bone density values in normal 
gender-matched young adults. T-score is used to make a diagnosis of normal bone density, 
osteoporosis or osteopenia in postmenopausal women and in men age 50 years and older 
(Leib et al, 2004). Z-scores represent the number of SDs from the normal mean value for age- 
and gender-matched control subjects. A Z-score of -2.0 or lower may suggest the presence of 
a secondary cause of osteoporosis, although no definitive data support this hypothesis. Z-
scores are used preferentially to assess bone loss in premenopausal women and men 
younger than age 50 years. A Z-score of -2.0 or lower is defined as “below the expected 
range for age”; a Z-score above -2.0 is “within the expected range for age.” (Leib et al, 2004). 
Originally, the definition of osteoporosis was developed for the estimation of the prevalence 
of osteoporosis across populations. It was not for the assessment of osteoporosis in 
individual patient. In other words, diagnostic thresholds differ from intervention 
thresholds. The fracture risk varies at different ages, even with the same T-score. Other 
factors that determine intervention thresholds include the presence of clinical risk factors 
(CRFs), costs and and benefits of treatment.  
4. Determination of fracture risk 
In the past decade, a great deal of research has taken place to identify factors other than 
BMD that contribute to fracture risk. The consideration of well-validated CRFs, with or 
without BMD, is likely to improve fracture risk prediction and the selection of individuals at 
high risk for treatment. Some of these risk factors act independently of BMD to increase 
fracture risk whereas others increase fracture risk through their association with reduced 
BMD (e.g., some of the secondary causes of osteoporosis) (Table 2) (Compston et al, 2009). 
Several models have been proposed to stratify osteoporotic fracture risk. These include 
strategies to identify patients with a high risk of low BMD (e.g., the OST index (Gensens et 
al, 2002), and the FRAX algorithm (Kanis, et al, 2008a, 2008b)) or with a high absolute risk of 
fractures based on CRFs, with or without BMD (e.g., FRAX algorithm (Kanis, et al, 2008a, 
2008b)), Fracture Risk in Glucocorticoid Users (FIGS) (van Staa et al, 2005), the Garvan 
algorithm (Nguyen et al, 2008)), and simplified questionnaires. 
Among these models, FRAX®, developed by WHO is an algorithm for individualized 
fracture risk prediction which is depend on population-based cohort from Europe, North 
America, Asia, and Australia.  
4.1 Use of WHO Fracture Risk Assessment Tool (FRAX
®
) 
FRAX® is a clinical tool for case finding for identifying patients at high risk for fractures, for 
selecting patients to measure BMD, and for treatment decisions. FRAX® should not be 
considered a gold standard but rather provides an aid to enhance patient assessment. The aim 
of FRAX® is to provide an assessment tool for the fracture prediction with use of CRFs with or 
without femoral neck BMD (Kanis et al, 2008a). These CRFs include age, sex, race, height, 
weight, body mass index (BMI), a history of fragility fracture, a parental history of hip fracture, 
use of oral glucocorticoid, rheumatoid arthritis, and other secondary causes of osteoporosis, 
current smoking, and alcohol intake of three or more units daily. These risk factors were 
identified and validated based on an analysis of 12 prospective studies, yielding a total of 
250,000 person-years in 60,000 men and women with more than 5,000 osteoporotic fractures 
(Kanis, 1994). Because fracture probability also varies markedly among different regions of the 
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world, FRAX® allows fracture risk to be calculated for countries where the incidences of both 
fractures and mortality are known (Unnanuntana et al, 2010). 
FRAX® has been developed for calculating the 10-year absolute fracture risk in individual 
patients in primary care settings for a major osteoporotic fracture (in the proximal humerus, 
the wrist, or the hip or a clinical vertebral fracture) and for a hip fracture calibrated to the 
fracture and death hazards. The relative risks are difficult to apply in clinical practice since 
their clinical significance depends on the prevalence of fractures in the general population. 
As a result, the concept of the absolute risk of fractures has emerged and refers to the 
individual’s risk for fracture over a certain time period, e.g., over the next 5 or 10 years 
which is the usual duration of the effects of osteoporosis medications during and after use 
(van Geel et al, 2010). 
The FRAX® algorithm is available at www.nof.org and at www.shef.ac.uk/FRAX. FRAX® is 
intended for postmenopausal women and men age 50 and older who have not been treated 
for osteoporosis; it is not intended for use in younger adults or children. 
NOF starts case finding with age as a criterion (NOF, 2011). Below 65 years, NOF advocates 
clinical attention for the presence of CRFs (those included in FRAX, with the addition of other 
risks), and a DXA in the presence of CRFs. In all women older than 65 years, NOF advocates 
BMD. Treatment is advocated in women with osteoporosis or osteoporotic fracture and in 
women with osteopenia if FRAX® calculation with BMD indicates a high risk of fracture or 
when specific high risks (total immobilization and glucocorticoid use) are present. 
 
 
* Not presently accommodated in the FRAX® algorithm 
Table 2. Clinical risk factors used for the assessment of fracture probability 
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The National Osteoporosis Society (NOS) starts case finding with CRFs of FRAX® in all 
postmenopausal women (Compston et al, 2009). Treatment is advocated in high-risk 
patients based on CRFs of FRAX without DXA and in patients with intermediate risk when 
BMD results integrated in FRAX® indicate a high risk. 
It should also be acknowledged that there are many other risk factors for fracture that are 
not incorporated into assessment algorithms. FRAX® does not include fall-related risk 
factors and other risk factors for fractures: dose and duration of some risk factors like 
glucocorticoid use; characteristics of previous fractures (location, number, and severity); 
vitamin D deficiency; and levels of biochemical markers of bone turnover (van Geel et al, 
2010). Moreover, no randomized clinical trials focusing on prevention of fractures in 
patients who are included based on FRAX® are available (van Geel et al, 2010). Further 
studies will be needed on the ability to treatment to reduce fracture risk in subjects at high 
risk for fractures based on FRAX®. Another drawback is that FRAX® is only applicable in 
treatment naïve patients (Saag, 2009).  
5. Clinical investigations 
Comprehensive approach to the clinical evaluation of osteoporosis is recommended. A 
detailed history and physical examination together with BMD assessment and the 10-year 
estimated fracture probability are utilized to establish the individual patient’s risk. The 
range of tests will depend on the severity of the disease, age at presentation, and the 
presence or absence of fractures. The aims of patient evaluation are to exclude diseases that 
mimic osteoporosis (e.g. osteomalacia, myeloma), identify the cause of osteoporosis and 
contributory factors, assess the risk of subsequent fractures and select the most appropriate 
form of treatment (Compston et al, 2009). 
5.1 History and physical examination 
Many metabolic bone diseases are associated with low BMD, therefore a complete and 
thorough history taking and physical examination are essential to establishing a correct 
diagnosis of osteoporosis. A complete history should be obtained, with specific attention 
given to the risk factors, including lifestyle, medical, family, and medication histories  
(Table 3) (NOF, 2010). Physical examination should include height and weight for BMI and 
determining any loss of height (historical height loss >4 cm). A thorough physical 
examination may detect kyphosis, a protruding abdomen, rib-iliac crest distance of less than 
2 cm, height loss (prospective height loss >2 cm), acute or chronic back pain and/or 
tenderness, reduced gait speed or grip strength, and poor visual acuity. Certain other 
findings, such as nodular thyroid, hepatic enlargement, jaundice, or cushingoid features 
may reveal secondary causes of osteoporosis (Lane, 2006). 
Since the majority of osteoporosis-related fractures result from falls, it is also important to 
evaluate risk factors for falling. The most important of these seem to be a personal history of 
falling, along with muscle weakness and gait, balance and visual deficits (Anonymous, 
2001). All elderly should be asked annually about the occurrence of falls. Any patient who 
reports a single fall should undergo basic evaluation of gait/balance (e.g., “Get Up and Go 
test”)(Anonymous, 2001). Items that should be included as a part of a fall risk assessment 
are summarized in Table 4 (NOF, 2010). 
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Table 3. Conditions, diseases, and medications that cause or contribute to osteoporosis and 
fractures  
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Table 4. Risk factors for falls 
5.2 Bone mineral density measurement 
Although central DXA of the hip (femoral neck or total hip) is the gold standard for 
diagnosing osteoporosis, many experts including the International Society for Clinical 
Densitometry (ISCD), recommend using the lowest central DXA T-score of posteroanterior 
lumbar spine (L1-L4), femoral neck, or total hip (or the 33% distal radius of the non-
dominant forearm, if measured) to make the diagnosis (Leib et al, 2004). DXA measurement 
of BMD at other sites (including the trochanter, Ward triangle, lateral lumbar spine, other 
forearm regions, heel, or total body) or with other technologies (calcaneal ultrasonography, 
peripheral DXA, quantitative computed tomography, single- or dual-photon radionuclide 
absorptiometry, or magnetic resonance imaging) are not recommended for use in 
diagnosing osteoporosis (Leib et al, 2004; Marshall et al, 1996). 
As a spine region of interest, posteroanterior L1-L4 for spine BMD measurement and only 
exclude vertebrae that are affected by local structural change (e.g., degenerative change or 
compression fracture) or artifact should be used (Baim et al, 2008). However, BMD based 
diagnostic classification should not be made using a single vertebra. If only one evaluable 
vertebra remains after excluding other vertebrae, diagnosis should be based on different 
valid skeletal site. 
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As a hip region of interest, femoral neck or total proximal femur, whichever is lowest should 
be used (Baim et al, 2008). Forearm BMD should be measured under the following 
circumstances: hip and/or spine cannot be measured or interpreted; hyperparathyroidism; 
and very obese patients (over the weight limit for DXA table) (Baim et al, 2008). 
Peripheral DXA (pDXA), quantitative computed tomography (QCT), and quantitative 
ultrasound densitometry (QUS) are also capable of predicting both site-specific and overall 
fracture risk (NOF, 2010). When performed according to accepted standards, these 
densitometry techniques are accurate and highly reproducible (USPSTF, 2002). However, T-
scores from these technologies cannot be used according to the WHO diagnostic 
classification because they are not equivalent to T-scores derived from DXA (NOF, 2010). 
Moreover, these measurements are less useful in predicting the risk of fractures of the spine 
and proximal femur than central DXA (Lane, 2006).  
The accuracy of QCT of the spine in predicting spinal fracture is comparable to that of DXA 
but has the advantage of measuring true volumetric or 3-dementional BMD, in contrast to 
the areal BMD obtained from DXA (Miller, 1999). QCT can distinguish between cortical and 
trabecular bone and thus is more sensitive to changes in BMD caused by the higher bone 
turnover rate of trabecular bone (Brunader & Shelton, 2002). It is also precise enough to 
detect BMD changes over time, and it can be used to follow the disease state or to monitor 
the response of osteoporosis therapy (Brunader & Shelton, 2002). For this reason, QCT are 
not the gold standard at the moment, but are also recommended (if applicable) to evaluate 
osteoporosis.  
5.3 Vertebral fracture assessment 
Morphometric vertebral fractures are the most frequent fractures in women and men older 
than 50 years (Sambrook & Cooper, 2006). Independent of BMD, age, and other CRFs, 
radiographically confirmed vertebral fracture is a strong predictor of future vertebral, non-
vertebral, and hip fracture risk (Lems, 2007). The presence of a vertebral fracture increases 
the relative risk of future vertebral fractures by 4.4-fold and increases the risk of fragility 
fractures at other skeletal sites as well (Klotzbuecher et al, 2000). The higher the grade 
(severity) of the existing vertebral fracture, or the more vertebral fractures present (one, two, 
or three), the greater the risk for future fractures (Gallagher et al, 2005; Black et al, 1999).  
Clinical vertebral fractures represent one out of three to four morphometric vertebral 
fractures (van Helden et al, 2008). Because most morphometric vertebral fractures are not 
diagnosed until clinically suspected and imaging by x-ray is performed, vertebral fractures 
are often missed.  
Imaging techniques to detect and evaluate vertebral fractures in clinical practice include plain 
radiography (x-ray), computed tomography (CT), magnetic resonance imaging (MRI) nuclear 
bone scanning, and vertebral fracture assessment (VFA). There are differences in each of these 
in terms of imaging resolution, radiation exposure, availability, cost, and patient convenience.  
Vertebral Fracture Assessment (VFA) is a new method to evaluate the presence of 
morphometric vertebral fractures and deformities using central DXA. VFA reliably and 
accurately identified patients with vertebral fractures that have not been recognized, with 
greater patient convenience, lower cost, and less radiation than standard x-ray. VFA is 
indicated when there is a probability that a prevalent vertebral fracture will influence 
clinical management of the patient (Lewiecki & Laster, 2006). The use of VFA contributes to 
better define the fracture risk in women with osteopenia and contributes to treatment 
decisions identifies patients at high risk of fractures in the absence of BMD-based osteoporosis. 
Indications for VFA according to the ISCD are presented in Table 5 (Baim et al, 2008). 
www.intechopen.com
 
Approach to the Screening and Diagnosis of Osteoporosis 
 
159 
 
Table 5. Indications for vertebral fracture assessment using x-ray absorptiometry 
5.4 Biochemical markers of bone turnover 
Bone turnover is the principal factor that controls both the quality and the quantity of bone 
in adult skeleton and it can be assessed by measuring biochemical markers in blood and 
urine samples. Bone turnover markers (BTMs) represent the products of bone formation and 
resorption that are released into the circulation (Table 6).  
 
 
Table 6. Markers of bone turnover  
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Quantitative changes in BTMs reflect the dynamic process of bone metabolism. BTMs have 
been associated with increased osteoporotic fractures independently of BMD in large 
prospective studies. They also may predict bone loss and, when repeated after 3 to 6 months 
of treatment with FDA approved antiresorptive drugs, may be predictive of fracture risk 
reduction. However, BTMs are not a substitute for DXA in women at risk. The value of 
BTMs in the assessment of fracture risk is likely to be in combination with risk factors, 
including BMD (Delmas et al, 2000). Generally, their use in the diagnosis of osteoporosis is 
not recommended (Lash et al, 2009). 
There are multiple factors that may cause variations in the levels of BTMs (Table 7). 
Therefore it is necessary to review certain factors that affect bone marker levels. The main 
source of variability is pre-analytical; mostly sample conservation and biological variability 
(Unnanuntana et al, 2010). Pyridinoline crosslinks are light sensitive and degraded under 
the influence of intense UV irradiation (Body et al, 2009). Osteocalcin concentrations are 
decreased by freeze-thaw cycles and hemolysis. Assays detecting only intact osteocalcin are 
particularly affected by in vitro degradation, so it may be advantageous to use assays 
recognizing both the intact molecule and the large N-terminal fragment (N-MID, 1–43 
amino acid), which appear to be more stable, sensitive and reproducible. (Delmas et al, 1985) 
Some osteocalcin fragments are also released during bone resorption (Delmas et al, 1990). In 
adults, the main source of undesirable biological variability is the circadian rhythm, with 
higher values in the early morning hours (peak in 4:00 A.M. and 8:00 A.M.), then a steep 
decrease in the morning, to attain a nadir at the end of the afternoon (through in 1:00 P.M. 
and 11:00 P.M.) (Seibel et al, 2005). Most BTMs follow the same pattern, with the exception 
of alkaline phosphatase because of its longer half-life. Practically, it implies that the 
measurement of BTMs must be performed in the same lab using standard procedures; 
samples should be taken while fasting and always at the same time of day. For the urinary 
BTMs, it is best to obtain either a 24-hour urine collection or morning second voided urine 
sample. Creatinine excretion also contributes to the overall variability in the levels of 
urinary BTMs (Unnanuntana et al, 2010). 
 
 
Table 7. Factors affecting levels of bone turnover markers 
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5.5 Laboratory tests 
Among men, 30% to 60% of osteoporosis cases are associated with secondary cause. Among 
perimenopausal women, more than 50% of cases are associated with secondary causes (NIH 
Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, 2001). 
In patients referred for DXA in the clinical context of an osteoporosis clinic, contributors to 
secondary osteoporosis were already documented in one out of three postmenopausal 
women, previously undiagnosed contributors were found in an additional 30% of women 
(Tannenbaum et al, 2002). 
General consensus exists among experts that a minimum screening laboratory tests should 
be considered for all patients who are diagnosed as having osteoporosis prior to treatment. 
Many experts have also suggested that patients who have osteoporosis and a Z-score of less 
than -2.0 should have more extensive laboratory tests for secondary cause of osteoporosis. A 
diagnosis of osteoporosis in men should also prompt a through work-up for secondary 
causes regardless of their Z-score (Mauck & Clarke, 2006). 
The range of laboratory tests will depend on the severity of the disease, age at presentation, 
and the presence or absence of fractures. In patients with BMD-based osteoporosis or 
presenting with a clinical fracture or both, diagnostic evaluation is necessary and should 
include blood cell count, sedimentation rate or C-reactive protein, serum calcium, phosphate, 
alkaline phosphatase, liver transaminase, albumin, creatinine, thyroid stimulating hormone 
(TSH) and 25(OH)D3. According to the clinical features and suspicion, other measurements 
such as parathyroid hormone (PTH), protein immunolelectrophoresis and urinary Bence-Jones 
proteins, serum testosterone, sex-hormone binding globulin (SHBG), follicle stimulating 
hormone (FSH), and luteinizing hormone (LH) in men, serum prolactin, 24-hour urinary 
cortisol/dexamethasone suppression test, endomysial and/or tissue transglutaminase 
antibodies, 24-hour urinary calcium and creatinine looking for secondary causes are indicated 
(Compston et al, 2009). If a specific secondary cause of osteoporosis is suspected on the basis of 
the history and physical examination findings, further direct testing is indicated.  
6. Conclusion 
Many factors are associated with osteoporosis and fracture, including low peak bone mass, 
hormonal factors, the use of certain medications, cigarette smoking, low physical activity, 
low calcium and vitamin D intake, race, small body size, and a personal or family history of 
fracture. All these factors should be taken into account when assessing the risk of fracture to 
determine which patients require further assessment and/or treatment. Clinical guidelines 
help guide practice but should not replace clinical judgment and patient preferences. The 
final decision about screening, assessment, and/or treatment is ultimately at the discretion 
of the physician and the patient. 
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